Edgar Filing: AUERBACH ALAN H - Form 4

AUERBACH	ALAN H									
Form 4 March 22, 201	0									
March 22, 2019 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations 										
1. Name and Add AUERBACH	2. Issuer Name and Ticker or Trading Symbol PUMA BIOTECHNOLOGY, INC. [PBYI]				>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Mo				3. Date of Earliest Transaction (Month/Day/Year) 03/04/2019			_X_ Director _X_ 10% Owner _X_ Officer (give title Other (specify below) PRESIDENT AND CEO			
				mendment, Date Original Ionth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
LOS ANGEL	ES, CA 9002	24						Form filed by M Person		
(City)	(State)	(Zip)	Table	I - Non-De	erivative S	ecurit	ies Acqu	iired, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction (Month/Day/Y	(ear) Execut any		Code (Instr. 8)		ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
COMMON STOCK	03/04/2019			S <u>(1)</u>	496	D	\$ 38.62	4,204,186	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

3. Transaction Date 3A. Deemed 7. Title and 4. 5. 6. Date Exercisable and (Month/Day/Year) Derivative Conversion Execution Date, if TransactionNumber Expiration Date Amount of or Exercise any Code of (Month/Day/Year) Underlying Price of (Month/Day/Year) (Instr. 8) Derivative Securities Derivative

(Instr. 3 and 4) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Amount

Code	V	(A)	(D))	Date Exercisable	Expiration Date	Title	of
Code	V	(A)	(D)				Shares

Reporting Owners

Security

Reporting Owner Name / Address	Relationships					
hopotang o man ramo, ramoso	Director	10% Owner	Officer	Other		
AUERBACH ALAN H C/O PUMA BIOTECHNOLOGY, INC. 10880 WILSHIRE BLVD., SUITE 2150 LOS ANGELES, CA 90024	Х	Х	PRESIDENT AND CEO			
O!						

Signatures

1. Title of 2.

Security

(Instr. 3)

/s/ Alan H.	
Auerbach	03/22/2019
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

2

8. Price of

Derivative

Security

(Instr. 5)

9. Nt

Deriv

Secu

Bene

Own

Follo

Repo

Trans

(Insti

Edgar Filing: AUERBACH ALAN H - Form 4